Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Income Statement [Abstract]        
Revenues
Costs and expenses:        
General and administrative costs, including $12,000 and $13,847 to related parties for the three months ended June 30, 2018 and 2017, respectively, and $24,000 and $29,691 to related parties for the six months ended June 30, 2018 and 2017, respectively 330,839 278,377 684,909 755,737
Research and development costs, including $64,615 to Theradex for the six months ended June 30, 2017 41,106 14,559 66,795 157,803
Total costs and expenses 371,945 292,936 751,704 913,540
Loss from operations (371,945) (292,936) (751,704) (913,540)
Interest income 525 152 1,124 164
Net loss $ (371,420) $ (292,784) $ (750,580) $ (913,376)
Net loss per common share – basic and diluted $ (0.01) $ (0.01) $ (0.01) $ (0.02)
Weighted average common shares outstanding – basic and diluted 58,025,814 57,678,012 58,025,814 53,577,471